Approximately 19,800 people die annually from MRSA, methicillin-resistant Staphylococcus aureus, in the United States alone. Many of these patients have already failed multiple generations of antibiotics. For them, a tool could arrive that medicine discovered 100 years ago and then ignored for decades: bacteriophages, viruses that selectively kill bacteria. US biotechnology company Armata Pharmaceuticals announced in January 2026, following a conclusion meeting with the FDA, that it will advance its phage therapy candidate AP-SA02 to the third clinical trial phase. It is the first time worldwide that a phage preparation has reached this milestone in Western medicine.
What are phages?
Phages are natural viruses that exclusively infect bacteria. They recognize their target cell through specific surface proteins, penetrate it, and destroy the bacterium from within. For human cells, they are harmless. The idea of using phages medically is around 100 years old and was continuously developed in the Soviet Union and Georgia while Western medicine lost interest after the discovery of antibiotics.
Antibiotics have been under pressure for decades: more pathogens develop resistance faster than new drugs are approved. According to the WHO, approximately 16 percent of all laboratory-confirmed infections worldwide were antibiotic-resistant in 2023. In Southeast Asia and the Eastern Mediterranean, this already affects one in three infections. Globally, approximately 1.14 million people died directly from antibiotic-resistant infections in 2021 according to estimates.
The path from Phase 1 to Phase 3
Armata Pharmaceuticals develops AP-SA02 as an intravenous cocktail of two natural lytic phage strains: ARSA0001 and ARSA0002. The FDA granted the candidate both Fast Track designation and Qualified Infectious Disease Product status (QIDP), which means accelerated review procedures and, after approval, five additional years of market exclusivity.
In October 2025, Armata presented results from the DISARM study (Phase 2a) at the IDWeek conference, the leading US conference for infectious diseases. The study enrolled 42 patients with complicated bacteremia from Staphylococcus aureus. Clinical response at day 12 of treatment was 88 percent in the AP-SA02 group versus 58 percent in the placebo group (p = 0.047). Relapse rates four weeks after therapy: zero percent in the treatment group, approximately 25 percent in the control group. In January 2026, the FDA concluded this meeting. Armata announced plans to initiate Phase 3 in the second half of 2026.
In comparison: how other therapies found their path to approval
New therapeutic principles typically require decades to reach approval. Checkpoint inhibitors, T-cell-based immunotherapies for cancer, have been studied since the 1980s. Ipilimumab became the first checkpoint inhibitor to receive FDA approval in 2011 for melanoma and transformed treatment for patients with no prior effective option. Today, checkpoint inhibitors are indispensable in oncology.
Another example: Hepatitis C was discovered in 1989. For decades, interferon was the only treatment, with cure rates of 40 to 50 percent and significant side effects. In 2014, sofosbuvir (Sovaldi) reached the market. Today, more than 95 percent of patients are cured in under twelve weeks. The phage pathway could unfold similarly: an old idea, long neglected, now advancing to practice through systematic clinical research.
According to the US Centers for Disease Control, MRSA causes approximately 19,800 annual deaths in the United States, associated with roughly 120,000 bloodstream infections. In Germany, approximately 132,000 MRSA cases per year are recorded in hospitals. Other biotechnology companies are working on similar approaches for different pathogens: Locus Biosciences is testing the CRISPR-enhanced phage cocktail LBP-EC01 against antibiotic-resistant Escherichia coli infections in a Phase 2/3 study.
Earliest 2028: the first commercial phage in Western medicine
A successful Phase 3 would be historic: the first commercially approved phage preparation in Western medicine. FDA approval could occur as early as 2028 or 2029 if Phase 3 succeeds.
Phage therapies have structural limitations: their spectrum of activity is very narrow. A phage cocktail that targets MRSA will not work against other pathogens. Bacterial resistance development against the phages is also possible. In polymicrobial infections with multiple organisms, phages fail as monotherapy. For the specific use case where antibiotics fail and patients have no alternative, an approved phage therapy would nevertheless be a tool intensive-care physicians have awaited for decades.